Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data

BACKGROUND: To evaluate incidence of opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with abatacept in clinical trials. METHODS: This pooled analysis of 16 randomized, double-blind/open-label trials, with ≥ 1 abatacept (intravenous or subcutaneous) arm, and with/wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, Teresa A., Dong, Lixian, Winthrop, Kevin L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798209/
https://www.ncbi.nlm.nih.gov/pubmed/33430948
http://dx.doi.org/10.1186/s13075-020-02399-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798209/
https://www.ncbi.nlm.nih.gov/pubmed/33430948
http://dx.doi.org/10.1186/s13075-020-02399-2

Ejemplares similares